VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 13, 2013) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) is pleased to announce that it has executed an agreement with the Stanford University School of Medicine, Department of Radiology, to test protein conjugates and multimers as part of APC's "Foundation Trinity™" technology involving targeted, combination, and homogeneous therapy in a single anti-cancer agent. Stanford will be testing APC's protein modifications to determine their effects on tumors in a variety of cancer disease states.
Dr. Alexander (Allen) Krantz, APC's President and CEO, stated that "we are extraordinarily fortunate in having Stanford's participation in our program involving cancer therapeutics. The School of Medicine's expertise is unrivaled in APC's areas of interest."
About APC
APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has an affinity for cancer cells. The Company anticipates that due to the high affinity for a target receptor on cancer cells, the protein can function as a transport system for multiple drug entities linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs, and delivering combination therapy in a single agent of high purity.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
(617) 638-0340
www.advancedproteome.com